LOS ANGELES, CA, USA I December 6, 2017 I Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, will present updated interim results from a Phase II clinical trial of Puma's drug neratinib at the 2017 San Antonio Breast Cancer Symposium (SABCS) that is currently taking place in…
News
- Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended ...
- SA biotech gains critical entry into European market
The San Antonio-based biotech company struck an agreement with a British company to market and distribute its stem cell products in the United Kingdom and in Western Europe. The deal with Caltag Medsystems Ltd. will initially involve StemBioSys' cell expansion products. But as StemBioSys…
- 'Most vulnerable' dying in 'America's Finest City'
More than 400 makeshift shelters sprung up downtown, covering sidewalks across from new high-rise apartment buildings that have climbed in lockstep with the booming biotech-heavy economy and soaring rents, among the nation's highest. A studio apartment goes for around $1,500 a month, ...…
- Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended ...
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, will present updated interim results from a Phase II clinical trial of Puma's drug neratinib at the 2017 San Antonio Breast Cancer Symposium (SABCS) that is currently taking place in San…
- Doctors identify brain abnormalities in Cuba attack patients
But acoustic waves have never been shown to alter the brain's white matter tracts, said Elisa Konofagou, a biomedical engineering professor at Columbia University who is not involved in the government's investigation. "I would be very surprised," Konofagou said, adding that ultrasound in the…